Pharmacy
Pharmacy Formulary and Prior Authorization Changes July 2025
May 15, 2025
Beginning July 2025, some drugs will experience a formulary drug list change. Visit premera.com to learn more about these changes.
Also beginning July 2025, the following drugs will require a new prior authorization:
Condition
Drugs requiring a new prior authorization
Preferred alternatives
Cancer support
- Nyvepria (pegfilgrastim-apgf)
- Fulphila (pegfilgrastim-jmdb)
- Udenyca (pegfilgrastim-cbqv)
- Udenyca On-body (pegfilgrastim-cbqv)
Inflammatory disease
- Humira (adalimumab)
- Adalimumab-adaz
- Adalimumab-adbm
- Adalimumab-ryvk
- Cyltezo (adalimumab-adbm)
- Simlandi (adalimumab-ryvk)
How we’re notifying members
Affected members received a letter in the mail in May 2025 notifying them of the change, or the members’ provider was notified of the change in our February 2025 Provider News.
If you have questions about these formulary and prior authorization changes, please contact your Premera representative.